甘李药业所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：创新药、生物医 药、医疗器械、多肽药、基金重仓等。 截至9月30日，甘李药业股东户数9.47万，较上期增加22.53%；人均流通股5889股，较上期减少 17.81%。2025年1月-9月，甘李药业实现营业收入30.47亿元，同比增长35.73%；归母净利润8.18亿元， 同比增长61.32%。 11月12日，甘李药业盘中上涨2.03%，截至09:50，报65.41元/股，成交1.78亿元，换手率0.49%，总市值 390.70亿元。 资金流向方面，主力资金净流入897.83万元，特大单买入652.78万元，占比3.68%，卖出325.78万元，占 比1.83%；大单买入4254.96万元，占比23.96%，卖出3684.13万元，占比20.75%。 甘李药业今年以来股价涨51.74%，近5个交易日涨1.92%，近20日跌7.73%，近60日涨7.21%。 资料显示，甘李药业股份有限公司位于北京市通州区漷县镇南凤西一路8号，成立日期1998年6月17日， 上市日期2020年6月29日，公司主营业务涉及重组胰岛素类似物原料药及注射剂的研 ...

Core Viewpoint - Kanghong Pharmaceutical has shown a significant stock price increase of 69.79% year-to-date, with a recent market capitalization of 29.72 billion yuan, indicating strong investor interest and potential growth in the pharmaceutical sector [1][2]. Financial Performance - For the period from January to September 2025, Kanghong Pharmaceutical reported a revenue of 3.624 billion yuan, reflecting a year-on-year growth of 6.23%, while the net profit attributable to shareholders was 1.033 billion yuan, up by 6.08% [2]. - The company has distributed a total of 2.038 billion yuan in dividends since its A-share listing, with 1.04 billion yuan distributed over the past three years [3]. Shareholder Information - As of October 20, 2025, the number of shareholders for Kanghong Pharmaceutical increased to 24,900, a rise of 3.53%, while the average number of tradable shares per shareholder decreased by 3.41% to 27,592 shares [2]. - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited holding 28.007 million shares, an increase of 730,000 shares from the previous period [3].

Company Overview - Yunnan Yixintang Pharmaceutical Group Co., Ltd. is located in Kunming, Yunnan Province, and was established on November 8, 2000. The company was listed on July 2, 2014. Its main business involves retail and wholesale of pharmaceuticals, with revenue composition as follows: Western and Chinese medicines 75.03%, others 9.86%, traditional Chinese medicine 8.56%, and medical devices and disinfectants 6.55% [1][2]. Stock Performance - As of November 12, Yixintang's stock price increased by 2.02%, reaching 14.14 CNY per share, with a market capitalization of 8.28 billion CNY. The stock has risen 12.85% year-to-date, with a 5.52% increase over the last five trading days [1]. - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on May 23, where it recorded a net buy of -4.0951 million CNY [1]. Financial Performance - For the period from January to September 2025, Yixintang reported a revenue of 13.001 billion CNY, a year-on-year decrease of 4.33%, and a net profit attributable to shareholders of 269 million CNY, down 8.17% year-on-year [2][3]. Shareholder Information - As of September 30, 2025, Yixintang had 37,500 shareholders, an increase of 10.53% from the previous period. The average number of circulating shares per shareholder decreased by 9.53% to 10,596 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 22.3144 million shares, an increase of 3.74 million shares from the previous period. Several new institutional shareholders have entered the top ten list [3]. Dividend Distribution - Since its A-share listing, Yixintang has distributed a total of 2.023 billion CNY in dividends, with 764 million CNY distributed over the past three years [3].

Core Viewpoint - Jinfa Technology's stock price has shown significant volatility, with a year-to-date increase of 116.69% but a recent decline in the last five and twenty trading days [2][3]. Stock Performance - As of November 12, Jinfa Technology's stock price was 18.51 CNY per share, with a market capitalization of 48.804 billion CNY [1]. - The stock has experienced a 2.01% drop on the day, with a trading volume of 1.01 billion CNY and a turnover rate of 0.21% [1]. - Year-to-date, the stock has risen by 116.69%, but it has decreased by 2.48% in the last five trading days and 9.09% in the last twenty days [2]. Financial Performance - For the period from January to September 2025, Jinfa Technology reported a revenue of 49.616 billion CNY, representing a year-on-year growth of 22.62% [3]. - The net profit attributable to shareholders for the same period was 1.065 billion CNY, reflecting a year-on-year increase of 55.86% [3]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 395,400, up by 94.23% from the previous period [3]. - The average number of circulating shares per shareholder decreased by 47.77% to 6,662 shares [3]. Dividend Distribution - Since its A-share listing, Jinfa Technology has distributed a total of 6.740 billion CNY in dividends, with 1.136 billion CNY distributed in the last three years [4]. Institutional Holdings - As of September 30, 2025, the sixth-largest circulating shareholder is Penghua CSI Sub-Segment Chemical Industry Theme ETF, holding 31.6477 million shares as a new shareholder [4]. - The seventh-largest shareholder, Southern CSI 500 ETF, holds 30.709 million shares, having decreased its holdings by 599,900 shares compared to the previous period [4].

Core Viewpoint - The stock of Hangya Technology has experienced fluctuations, with a current price of 24.43 CNY per share, reflecting a year-to-date increase of 41.87% but a recent decline over the past 20 and 60 days [1]. Company Overview - Hangya Technology, established on January 30, 2013, and listed on December 16, 2020, is located in Wuxi, Jiangsu Province. The company specializes in the research, production, and sales of aerospace engine blades, integral blades, and orthopedic implant forgings [1]. - The revenue composition of Hangya Technology is as follows: 91.40% from aerospace products, 7.62% from medical products, and 0.98% from other sources [1]. Financial Performance - For the period from January to September 2025, Hangya Technology reported a revenue of 530 million CNY, representing a year-on-year growth of 1.95%. However, the net profit attributable to the parent company was 77.87 million CNY, showing a decrease of 16.04% year-on-year [1]. - As of September 30, the number of shareholders decreased by 19.08% to 9,849, while the average circulating shares per person increased by 23.58% to 26,234 shares [1]. Dividend Information - Since its A-share listing, Hangya Technology has distributed a total of 129 million CNY in dividends, with 103 million CNY distributed over the past three years [2].

Core Viewpoint - Yingkang Life's stock price has shown a positive trend with a year-to-date increase of 19.89%, reflecting investor confidence in the company's growth potential in the medical services and equipment sector [1][2]. Financial Performance - For the period from January to September 2025, Yingkang Life achieved a revenue of 1.358 billion yuan, representing a year-on-year growth of 10.59% [2]. - The net profit attributable to the parent company was 86.839 million yuan, marking a year-on-year increase of 5.20% [2]. Stock Market Activity - As of November 12, Yingkang Life's stock price was 11.03 yuan per share, with a market capitalization of 8.266 billion yuan [1]. - The stock experienced a trading volume of 25.6755 million yuan, with a turnover rate of 0.37% [1]. - The main capital inflow was 2.7549 million yuan, with significant buying activity from large orders [1]. Company Overview - Yingkang Life, established on August 6, 1998, and listed on December 9, 2010, is based in Qingdao, Shandong Province [2]. - The company specializes in medical devices and services, focusing on cancer prevention, diagnosis, treatment, and rehabilitation [2]. - The revenue composition includes 77.47% from medical services and 22.53% from medical devices and consumables [2]. Shareholder Information - As of October 31, the number of shareholders was 20,600, an increase of 4.53% from the previous period [2]. - The average circulating shares per person decreased by 4.34% to 31,075 shares [2]. Dividend Information - Yingkang Life has distributed a total of 29.48 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3].

Core Viewpoint - JianKai Technology's stock price has shown significant volatility, with a year-to-date increase of 60.22%, but a recent decline in the last five trading days by 1.88% [2] Group 1: Stock Performance - As of November 11, JianKai Technology's stock price rose by 2.01% to 90.99 CNY per share, with a market capitalization of 5.519 billion CNY [1] - The stock has experienced a 6.11% increase over the past 20 days, while it has decreased by 9.19% over the last 60 days [2] - The company has appeared on the "Dragon and Tiger List" once this year, with a net buy of 39.1731 million CNY on July 21 [2] Group 2: Financial Performance - For the period from January to September 2025, JianKai Technology reported a revenue of 211 million CNY, reflecting a year-on-year growth of 13.47% [2] - The net profit attributable to the parent company for the same period was 40.7246 million CNY, marking a year-on-year increase of 24.72% [2] - Cumulatively, the company has distributed 178 million CNY in dividends since its A-share listing, with 99.8755 million CNY distributed over the last three years [3] Group 3: Shareholder Information - As of September 30, 2025, JianKai Technology had 6,608 shareholders, an increase of 23.19% from the previous period [2] - The average number of circulating shares per shareholder decreased by 18.83% to 9,178 shares [2] - Notably, CITIC JianKang A (002408) has exited the list of the top ten circulating shareholders [3]

Core Viewpoint - Nanjing South Medical Co., Ltd. (南卫股份) experienced a stock price decline of 2.11% on November 11, with a current price of 6.95 CNY per share, reflecting a total market capitalization of 2.009 billion CNY [1] Group 1: Stock Performance - The stock has increased by 59.77% year-to-date, with a 1.61% rise over the last five trading days and a 13.01% increase over the last 20 days, while it has decreased by 0.86% over the last 60 days [1] - As of September 30, the number of shareholders decreased by 16.70% to 12,000, while the average circulating shares per person increased by 20.05% to 23,992 shares [2] Group 2: Financial Performance - For the period from January to September 2025, the company reported a revenue of 447 million CNY, a year-on-year decrease of 1.70%, and a net profit attributable to shareholders of -24.93 million CNY, representing a significant year-on-year decline of 87.25% [2] - Cumulatively, the company has distributed 77.52 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3] Group 3: Business Overview - Nanjing South Medical Co., Ltd. specializes in the research, production, and sales of transdermal products, medical adhesive tapes, bandages, sports protection products, first aid kits, and nursing products [1] - The main revenue sources are as follows: adhesive bandages (39.59%), protective products (28.11%), adhesive tapes and bandages (22.54%), dressings (5.01%), first aid kits (2.63%), others (1.71%), and topical agents (0.40%) [1]

Core Viewpoint - Nanwei Medical's stock has shown a significant increase of 27.99% year-to-date, with a recent trading price of 84.60 CNY per share, indicating strong market interest and performance in the medical device sector [1][2]. Financial Performance - For the period from January to September 2025, Nanwei Medical achieved a revenue of 2.381 billion CNY, representing a year-on-year growth of 18.29%. The net profit attributable to shareholders was 509 million CNY, reflecting a growth of 12.90% [2]. - Cumulative cash dividends since the company's A-share listing amount to 978 million CNY, with 664 million CNY distributed over the past three years [3]. Stock Market Activity - As of November 11, the stock price of Nanwei Medical increased by 2.00% during trading, with a total market capitalization of 15.892 billion CNY. The trading volume reached 113 million CNY, with a turnover rate of 0.72% [1]. - The stock has experienced a recent net inflow of 2.881 million CNY from major funds, indicating positive investor sentiment [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 12,500, with an average of 15,009 circulating shares per person, a decrease of 1.36% from the previous period [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fifth largest with 3.6594 million shares, marking its entry as a new shareholder [3].

Core Insights - Aimeike's stock price increased by 2.04% to 159.69 CNY per share as of November 11, with a total market capitalization of 48.32 billion CNY [1] - The company has experienced a year-to-date stock price decline of 10.04%, but a recent 5-day increase of 5.11% [1][2] - Aimeike's main business involves the research, production, and sales of biomedical soft tissue repair materials, with a revenue composition primarily from injection products [1] Financial Performance - For the period from January to September 2025, Aimeike reported a revenue of 1.865 billion CNY, a year-on-year decrease of 21.49%, and a net profit of 1.093 billion CNY, down 31.05% year-on-year [2] - Cumulative cash dividends since Aimeike's A-share listing amount to 3.887 billion CNY, with 3.012 billion CNY distributed over the past three years [3] Shareholder Information - As of October 31, 2025, Aimeike had 57,400 shareholders, an increase of 2.63% from the previous period, with an average of 3,630 circulating shares per shareholder, a decrease of 2.56% [2] - Major shareholders include Hong Kong Central Clearing Limited and various ETFs, with notable reductions in their holdings [3]